Dr. Matthew Lunning, an expert in B-cell lymphomas, discusses CAR T-cell therapy's logistics and its efficacy against standard care in high-risk diffuse large B-cell lymphoma (DLBCL). Alongside him, Dr. Sonali M. Smith, a senior lymphoma investigator, shares insights on frontline and relapsed treatments for DLBCL and follicular lymphoma. They explore the potential of bispecific antibodies, comparing their effectiveness, patient suitability, and safety in various scenarios. Their conversation reveals the evolving strategies and personalized approaches in lymphoma treatment.
